Dr. Lee on the Evolving Treatment Paradigm in Relapsed/Refractory Multiple Myeloma
Hans Lee, MD, discusses the evolving treatment paradigm in relapsed/refractory multiple myeloma.
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
2 Clarke Drive Cranbury, NJ 08512